Invest In The Future
Of Early Detection
A Breakthrough At-Home Breath Test Fusing Nature and AI
Average sensitivity detecting 4 major cancer types
$20M+
Raised from leading investors and innovation grants
Featured on:
ONE TEST TO FIND THEM ALL
Designed To Detect 4 Major Cancers
Breast
Lung
Colorectal
Prostate
*The company may adjust or change its product rollout based on clinical, operational, or strategic considerations.
.png)
Developing a Non Invasive, At-Home Breath Test For Multiple Cancers
Takes just minutes to complete
Affordable and accessible
Non-invasive
No clinic visits required
Online prescription, no appointments or lost workdays
No side effects, no preparation needed
Product Enrollment Plan*
Takes just minutes to complete
Affordable and accessible
Non-invasive
No clinic visits required
Online prescription, no appointments or lost workdays
No side effects, no preparation needed
AI+ NATURE
= EARLY DETECTION AT SCALE
_edited.png)
Meet LUCID
A Breakthrough Platform Fusing Scent & Science To Redefine Cancer Screening At Scale
Natural Precision
when it comes to sensing abilities and detecting volatile organic compounds (VOCs), canines have a competitive edge unmatched by any device.
Hybrid Power
LUCID, a patent-pending Bio-AI Hybrid platform, combines a fusion-sensoric lab, advanced AI, VOC delivery systems, and big data, fusing cutting-edge tech with dogs’ extraordinary sense of smell.
Build For Scale
Starting with our CLIA-certified lab, LUCID is designed as a turnkey solution that can be easily deployed in labs worldwide, paving the way for a new era of non-invasive, multi-cancer early detection.
LUCID Screens Each Sample
In Under One Second!
Study Shows SpotitEarly's High Accuracy
The Rainbow Study, a large-scale observational double blind clinical performance trial, measured the effectiveness and accuracy of SpotitEarly’s breath test in detecting the 4 most common types of cancer at all stages, using breath samples.
.png)
.png)
Sensitivity
Specificity
Specificity
Sensitivity
.png)
.png)
Increasing Adoption of Cancer Screening
"By combining AI with a dog’s powerful sense of smell, SpotitEarly is making early detection for multiple cancers faster, more accessible, and more affordable than anything I’ve seen in the field. This is a true breakthrough, and a chance to save lives at scale״
Prof. David Sidransky
Professor of Oncology at Johns Hopkins School of Medicine Specializes in biomarkers.
Backed by industry leaders, Invest alongside them
Leading VC partners
Hanaco VC
New York and Tel Aviv based venture capital fund that invests in the most promising emerging start ups from the Israeli ecosystem.
Menomedin Foundation
The Menomadin Foundation invests in business initiatives that have the potential to create long-term, sustainable social and environmental impact.
V Ventures
Based in Singapore and Thailand, V Ventures is backed by a well-diversified pool of investors, entrepreneurs, and executives from the world’s top technology and financial firms.
Exceptional Private Investors
Jeff Swartz
Formerly CEO of Timberland
Avishai Avrahami
CEO and Co-Founder of Wix
Michael Eisenberg
Co-founder and GP of Aleph VC
Sunny Sassoon
Chairman of Coffee Bean & Tea Leaf
Mitch Julis
Co-founding partner of Canyon partners hedge fund
Yair Lowenstein
Owner and CEO of Altshuler Shaham Financial
.png)
A Limited-Time Opportunity
Our Regulation A+ offering is now open to the public. Invest at $7.15 per share, with bonus shares of up to 8% available to individual investors. Larger investment amounts may qualify for volume-based pricing adjustments of up to 35%, subject to eligibility and investment size. Pricing may change or the offering may be modified or terminated at any time.
This is your opportunity to support and grow with life changing innovation!
Our Advisory Board
Our advisors are respected experts in their fields who have joined us in fighting cancer, adding their rich experience and knowhow to our common efforts.
.jpg)
Professor of Oncology at Johns Hopkins School of Medicine Specializes in biomarkers.
Multi-industry executive, 10+ years scaling molecular diagnostics from startup to public, 1M+ samples annually.
Director and founder of the The Suzanne Levy-Gertner Oncogenetics Unit at the Sheba Medical Center.
Head of Immunology & Tumor Diagnosis Lab at the Oncology Department of Hadassah Medical Center.
“The importance of innovation in cancer detection has never been greater”
Discount
Investment
up to 35% Volume Discount
Your SpotitEarly investment details:
Discount
3%
Share price
S 7.15
Total shares
2,256
Investments of $250K to $20M may qualify for volume-based pricing adjustments of up to 35%, subject to eligibility.
Standard Range?
View Your Terms
Set up Your Investment
Higher Range?
View Your Terms
Your SpotitEarly investment details:
Share Price
$ 7.15
Shares
0
+ Bonus Shares
0%
Total Shares w/Bonus
0
Bonus starts at $5,000 (3%).
Increase to $5,000
up to 8% Volume Based Bonus
Bonus
Investment
Set up Your Investment
Enter Your Investment Amount:
select your investment amount
get up to 25% off your share price
Everyday investor
discount
Investment
Accredited Investor
Earns $200K+ a year or has $1M+ net worth
(
)
Im an
Accredited investor?
See your options
-
2%
3%
4%
share price
S 6.87
Total shares
2,256
Bonus
3%
Bonus
3%
Total w/Bonus
2,324
Youre $500 away from your next
4% bonus (+72 shares)
select your investment amount
get up to 25% off your share price
discount
Investment
$1K
$5K
$10K
$20K
2%
3%
4%
5%
6%
8%
10%
12.5%
15%
20%
25%
$50K
$100K
$200K
$250K
$500K
$1M
$5M
$10M+
Everyday investor
Accredited Investor
Earns $200K+ a year or has $1M+ net worth
(
)
Im an
Everyday investor?
See your options
share price
S 6.87
Total shares
2,256
Bonus
3%
Bonus
3%
Total w/Bonus
2,324
Youre $30,000 away from your next
5% bonus (+72 shares)
Reasons To Invest
AI + Canines
Fusing AI precision with one of nature’s most intuitive diagnostic tools unlocking a potential unmatched by any device
Accurate
Our clinical study demonstrated 94% sensitivity and specificity for early-stage cancer detection
Scale
Our proprietary system is a turnkey, high-throughput solution, potentially enabling over 1 million annual tests in each SpotitEarly-powered screening facility
Cost Of Cancer
The economic burden of cancer care in the US will exceed to $245B by 2030
Home Test
Revolutionizing testing, no clinic visits needed. Home collection, easy return, online results